erlotinib hydrochloride has been researched along with Forestier-Certonciny Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Martino, V; Prati, C; Verhoeven, F; Weil-Verhoeven, D; Wendling, D | 1 |
1 other study(ies) available for erlotinib hydrochloride and Forestier-Certonciny Syndrome
| Article | Year |
|---|---|
Polymyalgia rheumatica occurrence under multikinase inhibitors (sorafenib and erlotinib) treatment.
Topics: Aged; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Glucocorticoids; Humans; Liver Neoplasms; Male; Polymyalgia Rheumatica; Positron Emission Tomography Computed Tomography; Prednisone; Protein Kinase Inhibitors; Sorafenib | 2019 |